admin

If you’re the type that throws caution to the wind, these deflated but intriguing growth stocks to buy may liven up your portfolio in the long run. Bloom Energy (BE): Although the fuel-cell specialist suffered a poor earnings report, the underlying message has become even more critical. Rivian Automotive (RIVN): Highly risky due to supply
0 Comments
In this article SOFI Pedestrians walk by the SoFi Technologies headquarters on February 22, 2022 in San Francisco, California. Justin Sullivan | Getty Images Shares of SoFi fell sharply on Tuesday and were halted after the company accidentally released its first-quarter results early. The company said the report, which was scheduled for after market close
0 Comments
With Twitter (NYSE:TWTR) and TWTR stock facing multiple, tough threats and possessing no major positive catalysts, I recommend that investors sell the shares. Overall, the biggest threat facing Twitter and its shares is the possibility that the takeover of the company — led by Tesla (NASDAQ:TSLA) CEO Elon Musk — will not close. Such an outcome
0 Comments
Twitter (TWTR) stock is still selling for $5/share less than Elon Musk’s offer. Musk has the money lined up thanks to SpaceX. What happens after the purchase isn’t your problem. Source: rafapress / Shutterstock.com Since Elon Musk said he would buy Twitter (NYSE:TWTR) for $54.20/share, about $44 billion, shares haven’t traded over $52. Twitter opened
0 Comments
Nio (NIO) offers Tesla (TSLA) luxury without the production volumes. The company has stiff competition within China, and those competitors are now exporting. Nio will likely remain small, and investors should demand a profit. Source: Robert Way / Shutterstock.com At this point in the game, investing in Nio (NYSE:NIO) stock means investing in the Chinese
0 Comments
Novavax’s Covid-19 vaccine still isn’t approved for use in the U.S. With the pandemic in full retreat and the majority of people now fully vaccinated, demand for Novavax’s vaccine is likely to be weak. Rival pharmaceutical companies Pfizer and Moderna have beat Novavax to market with multiple Covid-19 treatments. Source: rarrarorro / Shutterstock.com Any hope
0 Comments